Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8600008 | 0.98 | FDPS (0.60) | FDPSLMNACYP3A4NFKB1BLM | |
| SCHEMBL1815322 | 0.93 | FDPS (0.61) | FDPSLMNACYP3A4NFKB1BLM | |
| SCHEMBL10863085 | 0.87 | FDPS (0.76) | FDPSLAP3 | |
| SCHEMBL20699855 | 0.84 | FDPS (0.75) | FDPSLAP3 | |
| Monoethanolamine SCHEMBL11749890 | 0.80 | FDPS (0.78) | FDPSLAP3 | |
| SCHEMBL5059579 | 0.79 | FDPS (0.55) | FDPSLMNACYP3A4NFKB1BLM | |
| SCHEMBL3029102 | 0.79 | LAP3 (0.67) | FDPSLMNACYP3A4NFKB1BLM | |
| SCHEMBL27305210 | 0.79 | LAP3 (0.67) | FDPSLMNACYP3A4NFKB1BLM | |
| SCHEMBL2321372 | 0.79 | FDPS (0.70) | FDPS | |
| SCHEMBL5832092 | 0.78 | FDPS (0.64) | FDPSLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5641762-A | TREATING DEGENERATIVE BONE DISORDERS BY ADMINISTERING COMPOUND FORMED BY REACTING BRIDGING AGENT WITH CARBONIC ANHYDRASE INHIBITOR, THEN WITH BONE SEEKING AGENT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-06-24 | — | — | US | claimed |
| EP-2155769-B1 | TISSUE DEGENERATION PROTECTION | UNIV LEUVEN KATH (BE) | 2012-06-27 | — | — | EP | disclosed |
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-01-19 | — | — | US | disclosed |
| US-20100311860-A1 | METHOD FOR MAKING PROTON CONDUCTING MEMBRANES FOR FUEL CELLS BY RADIOGRAFTING | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-12-09 | — | — | US | disclosed |
| WO-2010081204-A2 | ACTIVATORS OF THE AUTOPHAGIC PATHWAY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-07-22 | — | — | WO | disclosed |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | disclosed |
| EP-2155769-A2 | TISSUE DEGENERATION PROTECTION | Katholieke Universiteit Leuven (BE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008134828-A2 | TISSUE DEGENERATION PROTECTION | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-11-13 | — | — | WO | disclosed |
| US-20080249016-A1 | Use of GLP-2 in a combination treatment for bone-related disorders | SANOS BIOSCIENCE A/S | 2008-10-09 | — | — | US | disclosed |
| US-7371721-B2 | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes | SANOS BIOSCIENCE A/S (DK) | 2008-05-13 | — | — | US | disclosed |
| US-5451401-A | Diphosphonic acid esters as tartar control agents | THE PROCTER & GAMBLE COMPANY (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0662075-A1 | PROSTAGLANDIN ANALOG FOR TREATING OSTEOPOROSIS | MERCK & CO. INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| US-5409911-A | Prostaglandin analog for treating osteoporosis | MERCK & CO., INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1995008979-A1 | DIPHOSPHONIC ACID ESTERS AS TARTAR CONTROL AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-04-06 | — | — | WO | disclosed |
| EP-0592488-A1 | DIMETHYLAMINO-HYDROXY-ALKAN DIPHOSPHONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | INSTITUTO GENTILI S.P.A. (IT) | 1994-04-20 | — | — | EP | disclosed |
| WO-1994006750-A1 | PROSTAGLANDIN ANALOG FOR TREATING OSTEOPOROSIS | MERCK & CO., INC. (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0586521-A1 | CALCIUM, TRACE MINERAL, VITAMIN D AND DRUG THERAPY COMBINATIONS | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1993000348-A1 | DIMETHYLAMINO-HYDROXY-ALKAN DIPHOSPHONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ISTITUTO GENTILI S.P.A. (IT) | 1993-01-07 | — | — | WO | disclosed |
| WO-1992021355-A1 | CALCIUM, TRACE MINERAL, VITAMIN D AND DRUG THERAPY COMBINATIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | BECN1, SQSTM1, ATG7 | FDPS 2066/4885LMNA 1258/4885CYP3A4 3462/4885 |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | SORD, CASP3, TXNRD2 | FDPS 2003/4885LMNA 1351/4885CYP3A4 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.